{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:14:02Z","timestamp":1759497242083},"reference-count":18,"publisher":"Japanese Society of Toxicology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2018]]},"DOI":"10.2131\/jts.43.685","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T22:39:45Z","timestamp":1541543985000},"page":"685-695","source":"Crossref","is-referenced-by-count":2,"title":["Approaches of validation of a 2-week combined repeated oral dose toxicity study with plasma micro sampling toxicokinetics (PMS-TK) in common marmosets"],"prefix":"10.2131","volume":"43","author":[{"given":"Hidemi","family":"Mochizuki","sequence":"first","affiliation":[{"name":"Ina Research Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Murota","sequence":"additional","affiliation":[{"name":"Ina Research Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Ina Research Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Nii","sequence":"additional","affiliation":[{"name":"Sumika Chemical Analysis Service, Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Kouhei","sequence":"additional","affiliation":[{"name":"Sumika Chemical Analysis Service, Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Sumika Chemical Analysis Service, Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Inoue","sequence":"additional","affiliation":[{"name":"Central Institute for Experimental Animals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiyoko","family":"Nishime","sequence":"additional","affiliation":[{"name":"Central Institute for Experimental Animals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tsutsumi","sequence":"additional","affiliation":[{"name":"Central Institute for Experimental Animals"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Bergers, W.W., van de Meent-van der Horst, D. and Joosen, M.J. (2004): Respiration-based measurement of lung deposition of a fluorescent dextrane aerosol in a marmoset monkey. Inhal. Toxicol., 16<\/b>, 141-146.","DOI":"10.1080\/08958370490270963"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Diehl, K.H., Hull, R., Morton, D., Pfister, R., Rabemampianina, Y., Smith, D., Vidal, J.M. and van de Vorstenbosch, C.; European Federation of Pharmaceutical Industries Association and European Centre for the Validation of Alternative Methods. (2001): A good practice guide to the administration of substances and removal of blood, including routes and volumes. J. Appl. Toxicol., 21<\/b>, 15-23.","DOI":"10.1002\/jat.727"},{"key":"3","doi-asserted-by":"crossref","unstructured":"David, J.M., Dick, E.J. Jr. and Hubbard, G.B. (2009): Spontaneous pathology of the common marmoset (Callithrix jacchus<\/i>) and tamarins (Saguinus oedipus, Saguinus mystax<\/i>). J. Med. Primatol., 38<\/b>, 347-359.","DOI":"10.1111\/j.1600-0684.2009.00362.x"},{"key":"4","unstructured":"FDA. (1996): NDA#020665, Review and evaluation of pharmacology and toxicology data. (https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/pre96\/020665_s000.pdf)"},{"key":"5","unstructured":"ICH. (2009): Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2)."},{"key":"6","unstructured":"ICH. (2017): Questions and answers to ICH S3A: Note for guidance on toxicokinetics: The assessment of systemic exposure in toxicity studies focus on microsampling S3A Q&As."},{"key":"7","unstructured":"Layne, D.G. and Power, R.A. (2003): Husbandry, handling, and nutrition for marmosets. Comp. Med., 53<\/b>, 351-359."},{"key":"8","unstructured":"Mansfield, K. (2003): Marmoset models commonly used in biomedical research. Comp. Med., 53<\/b>, 383-392."},{"key":"9","unstructured":"Ministry of Health, Labour and Welfare of Japan. (2010): Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals."},{"key":"10","doi-asserted-by":"crossref","unstructured":"Okano, H., Hikishima, K., Iriki, A. and Sasaki, E. (2012): The common marmoset as a novel animal model system for biomedical and neuroscience research applications. Semin. Fetal Neonatal Med., 17<\/b>, 336-340.","DOI":"10.1016\/j.siny.2012.07.002"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Orsi, A., Rees, D., Andreini, I., Venturella, S., Cinelli, S. and Oberto, G. (2011): Overview of the marmoset as a model in nonclinical development of pharmaceutical products. Regul. Toxicol. Pharmacol., 59<\/b>, 19-27.","DOI":"10.1016\/j.yrtph.2010.12.003"},{"key":"12","unstructured":"PMDA. (2000): Diovan\u00ae<\/sup> tablet regulatory application information, general information available for Diovan\u00ae<\/sup> tablet 20 mg, 40 mg, 80 mg (valsartan). 217-219. (http:\/\/www.pmda.go.jp\/drugs\/2000\/g000906\/index.html)"},{"key":"13","doi-asserted-by":"publisher","unstructured":"Poswillo, D.E., Hamilton, W.J. and Sopher, D. (1972): The marmoset as an animal model for teratological research. Nature, 239<\/b>, 460-462.","DOI":"10.1038\/237460a0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Shah, J.V., Parekh, J.M., Shah, P.A., Shah, P.V., Sanyal, M. and Shrivastav, P.S. (2017): Application of an LC-MS\/MS method for the analysis of amlodipine, valsartan and hydrochlorothiazide in polypill for a bioequivalence study. J. Pharm. Anal., 7<\/b>, 309-316.","DOI":"10.1016\/j.jpha.2017.06.001"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Smith, D., Trennery, P., Farningham, D. and Klapwijk, J. (2001): The selection of marmoset monkeys (Callithrix jacchus) in pharmaceutical toxicology. Lab. Anim., 35<\/b>, 117-130.","DOI":"10.1258\/0023677011911444"},{"key":"16","doi-asserted-by":"crossref","unstructured":"\u2019t Hart, B.A., Abbott, D.H., Nakamura, K. and Fuchs, E. (2012): The marmoset monkey: a multi-purpose preclinical and translational model of human biology and disease. Drug Discov. Today, 17<\/b>, 1160-1165.","DOI":"10.1016\/j.drudis.2012.06.009"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Uno, Y., Uehara, S. and Yamazaki, H. (2016): Utility of non-human primates in drug development: comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes. Biochem. Pharmacol., 121<\/b>, 1-7.","DOI":"10.1016\/j.bcp.2016.06.008"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Yamaguchi, A., Kohno, Y., Yamazaki, T., Takahashi, N., Shinki, T., Horiuchi, N., Suda, T., Koizumi, H., Tanioka, Y. and Yoshiki, S. (1986): Bone in the marmoset: a resemblance to vitamin D-dependent rickets, type II. Calcif. Tissue Int., 39<\/b>, 22-27.","DOI":"10.1007\/BF02555736"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/43\/11\/43_685\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T22:24:18Z","timestamp":1572560658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/43\/11\/43_685\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.43.685","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}